Live Radar: Primary PubMed, FDA MedWatch & CMS NADAC Verified • Updated Daily at 5:30 A.M. EST
★ Daily Top 10 Edition • 100% Free & Zero Pharma Ads

Sleep, Brain & Mood News: What Headlines Claim vs. What the Data Really Shows.

2:00 A.M. cortisol wakes, smartwatch sleep-score anxiety, dementia prevention trials, and nervous-system recovery.

  • ✓ Media Spin vs. Federal Receipts: We show the real Absolute Risk Reduction (ARR) and sample size (N) behind viral headlines.
  • ✓ Practical 3-Step Game Plan: Every story ends with what to check on your bottle, pharmacy receipt, or portal lab report today.
dotMD Health TV
📺 Doctor Mike • 10:07 JEV 99/100
Source ↗
Doctor Mike • 2026-11-04 FDA DailyMed Imprint Check • CMS NADAC Ledger

The Pharmacy Nearly Killed My Patient

Kitchen-Table Takeaway: Doctor Mike walks through how a look-alike/sound-alike pharmacy dispensing error nearly harmed a patient—and how checking your bottle’s NDC and FDA DailyMed pill imprint protects your family.
Up Next in Today’s Rotation Most Watched • 14-Day No-Repeat
1. Today’s Top Stories • Federal Receipts Included

Sleep, Brain & Mood News (1 Stories)

Updated Daily • Primary PubMed & Federal Data Verified
Up to 35%–40% Error in Wrist "Deep vs. REM" Staging

Did Your Smartwatch Tell You Your "Recovery Score" Is 42% Today? Why Sleep Doctors Say Wrist Sensors Are Giving Healthy People Insomnia

We compared wrist photoplethysmography (PPG) validation studies against hospital ECG and sleep-lab polysomnography (PMID 32345045) to show you what your watch gets right (resting heart rate) and what it guesses wrong (deep sleep minutes and daytime HRV).

The Plain-English Reality Check (PMID 32345045)

In head-to-head sleep lab validation studies published in Sleep (PMID 32345045), researchers hooked adults up to gold-standard polysomnography (scalp EEG wires that directly measure brain waves, eye movements, and muscle tone) while they wore leading consumer smartwatches on their wrists . The verdict: wrist wearables are very good (~88%–93% accurate) at telling when you fell asleep and when you woke up, and 97%+ accurate at measuring overnight Resting Heart Rate (RHR) . However, because a watch on your wrist cannot read brain waves, its guesses at "Deep Sleep vs. Light Sleep vs. REM" disagreed with hospital EEG brain-wave recordings 30% to 45% of the time !

#1 Action Step: 1. Practice the "Coffee First, App Second" rule every morning
3. Journalist & Media Press Room

Weekly Federal Data & Clinical Trial Press Releases

Media Contact: audit@dotmd.com
Press Release #1 DOTMD-PR-2026-W45-01

dotMD.com Federal Drug-Invoice Audit Reveals Pharmacies Acquire 10 Everyday Generic Prescriptions for Under $3.00/Month While Consumers Pay $15 to $118 in Copays and Retail Cash Markups

A new federal pharmacy-invoice audit released today by the dotMD.com Research Desk reveals that ten of the most commonly prescribed generic medications in the United States—accounting for over 412 million annual refills—cost retail pharmacies between $0.90 and $2.94 for a 30-day supply according to official Centers for Medicare & Medicaid Services (CMS) National Average Drug Acquisition Cost (NADAC) records, even as insured patients routinely pay $15 to $45 in Tier-1/Tier-2 insurance copays and uninsured cash buyers face $48 to $140 walk-in retail prices.

CMS-NADAC / PMID 38416590 Open Press Kit →
Press Release #2 DOTMD-PR-2026-W45-02

dotMD.com Audit of Landmark 3-Year NEJM Tirzepatide Study Translates Viral "94% Diabetes Prevention" Headlines Into Plain-English Absolute Risk Numbers (ARR = 12.1%, NNT = 9) and Highlights 17-Week Off-Treatment Rebound

Following widespread media headlines proclaiming that once-weekly tirzepatide (Zepbound/Mounjaro) "wipes out 94% of diabetes risk," a primary biostatistical audit published today by the dotMD.com Research Desk breaks down the actual 176-week New England Journal of Medicine SURMOUNT-1 trial (PMID: 39536238, N = 1,032) into transparent patient numbers: while relative risk fell by up to 93%–94%, the actual Absolute Risk Reduction (ARR) was 12.1 percentage points (1.3% progression on tirzepatide vs. 13.3% on placebo, Number Needed to Treat = 9) at an average 3-year cash drug cost of roughly $38,000 per patient.

PMID 39536238 Open Press Kit →
Press Release #3 DOTMD-PR-2026-W45-03

dotMD.com Molecular Weight Audit Exposes the "One-Capsule 500 mg Magnesium Glycinate" Physics Trap Across Best-Selling Online Sleep Supplements

An investigation of popular sleep and stress supplements conducted by the dotMD.com Research Desk using the National Institutes of Health (NIH) Dietary Supplement Label Database (DSLD) warns consumers that any product claiming to deliver 400 mg to 500 mg of elemental magnesium from pure magnesium glycinate in a single standard capsule violates basic physical chemistry. Because anhydrous magnesium bisglycinate (C4H8MgN2O4, molar mass 172.31 g/mol) is only 14.1% elemental magnesium by weight, delivering 400 mg of real elemental magnesium requires 2,837 mg of powder—physically requiring three to four Size-00 capsules.

NIH-DSLD / PMID 28445426 Open Press Kit →